The report, titled “Global Covid-19 Oral Medicine Market” analyzes the market for covid-19 oral medicines worldwide based on the type of drug distribution channel, final consumer, and geography. A comprehensive report offers an in-depth analysis of the market size for the past and the future along with an analysis of trends. RationalStat offers an analysis of the market share and production capabilities of the most prominent companies, Covid-19’s impact analysis, and a summary of competition, market strategies, and growth opportunities for the companies analysed in the covid-19 market study.
Market overview and dynamics: rising investment and initiatives of private and public sector players are expected to propel the expansion of the oral medicine market for covid-19 in the near future.
The covid-19 oral medicine market is anticipated to grow at a rate of 10.5 percent during the 2022-2028 forecast. The increase in the demand for biological medicines for the treatment of coronavirus has led to an increase in the sale of oral antivirals in recent years.
- The increasing number of patients living in the home health care setting and the increase in awareness of self-management, offer huge growth opportunities for the oral antivirals sector. But, a lack of knowledge and understanding could hinder growth due to oral pharmacological effects that are a result of the first pass of metabolism.
- The month of August, 2021 the World Health Organization (WHO) published a report that stated that Artesunate Imatinib, imatinib, as well as infliximab are three promising treatments being evaluated in the most recent part of its world Solidarity clinical trials in order to identify the most effective COVID-19 treatment options.
- Furthermore, the governments of different economies also introduced benefits such as reimbursement policies to help boost sales of oral medications across the region. Similar to the Indian government, they introduced reimbursement policies to ease the burden of COVID-19.
Segmental Analysis
- Based on end users, Hospitals hold a dominant share in the global covid-19 oral medicine market whereas demand from clinics and research institutes holds a significant share of the demand of covid-19 oral medicine market.
- Based on region, Asia Pacific holds a prominent share of the global covid-19 oral medicine market due to increased significant developments in major economies like China and India and supports lucrative growth opportunities in the region.
Competition Analysis: The growing efforts of the government are creating opportunities for the covid-19 oral medicine market to grow in the upcoming years
Due to the presence of many well-established companies in the global covid-19 oral medicine market, there is intense competition in the global covid-19 oral medicine market. Rising demand for oral antivirals owing to the covid-19 breakout and increasing government are expected to spike the demand for covid-19 oral medicine market in the upcoming years.
Acquisitions, product launches, and partnerships are the identified industry trends in the global covid-19 oral medicine market. Key market players adopt various strategies in order to reinforce their market share and gain a competitive edge over other competitors in the market. These players adopt various strategies in order to reinforce their market share and gain a competitive edge over other competitors in the market.
- In March 2021, Pfizer Inc. announced the initiation of a PHASE 1 study of a new oral antiviral therapeutic agent against SARS-COV-2.
- In October 2020, Atea Pharmaceuticals Inc. collaborated with Roche to jointly develop AT-527, a direct-acting antiviral (DAA), in Phase-2 clinical trials.
RationalStat has identified key players in the global COVID-19 oral medicine market, including Pfizer Inc., Merck & Co., Inc., Ridgeback Biotherapeutics, Strides Pharma Science Limited, Atea Pharmaceuticals, F. Hoffmann-La Roche Ltd., Emcure, Glenmark Pharmaceuticals Ltd., BioNTech SE, Dr. Reddy’s Laboratories Ltd., Novartis AG, Molecular Partners, among others. To maintain their market position, the key players in the COVID-19 oral medicine market focus on various growth strategies such as partnerships, collaborations, geographical expansion, product launches, etc.
RationalStat has segmented the global covid-19 oral medicine market on the basis of drug class, distribution channel, end user, and region.
- By Drug Class
- Antiviral
- Anticoagulant
- Monoclonal Antibodies
- Immune Modulators
- Others (Sedatives etc.)
- By Distribution Channel
- Offline
- Online
- By End User
- Hospitals
- Clinics
- Home Settings
- Others (Academic & Research Institutes)
- By Region
- North America
- US
- Canada
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Western Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Rest of Eastern Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- ASEAN (Indonesia, Vietnam, Malaysia, etc.)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- South Africa
- Turkey
- Rest of the Middle East & Africa
- North America
For more information about this report https://store.rationalstat.com/store/covid-19-oral-medicine-market-investment-growth-opportunity-analysis/
About RationalStat LLC
RationalStat is an end-to-end US-based market intelligence and consulting company that provides comprehensive market research reports along with customized strategy and consulting studies. The company has sales offices in India, Mexico, and the US to support the middle east and diversified businesses. The company has over 80 consultants and industry experts, developing more than 850 market research and industry reports for its report store annually.
RationalStat has strategic partnerships with leading data analytics and consumer research companies to cater to the client’s needs. Additional services offered by the company include consumer research, country reports, risk reports, procurement intelligence, data analytics, and analytical dashboards.
Contact
RationalStat LLC
Kimberly Shaw, Content and Press Manager
[email protected]
Phone: +1 302 803 5429
